{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Uterus&page=2", "query": { "condition": "Carcinoma of the Uterus", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 353, "total_pages": 36, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Uterus&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+of+the+Uterus&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T21:03:25.826Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00030498", "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Mixed Glioma", "Adult Myxopapillary Ependymoma", "Adult Oligodendroglioma", "Adult Pilocytic Astrocytoma", "Adult Primary Hepatocellular Carcinoma", "Adult Subependymoma", "Advanced Adult Primary Liver Cancer", "Advanced Malignant Mesothelioma", "Male Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Brain Tumor", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Malignant Mesothelioma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage II Esophageal Cancer", "Stage II Pancreatic Cancer", "Stage III Esophageal Cancer", "Stage III Pancreatic Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-06T21:03:25.826Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030498" }, { "nct_id": "NCT06792552", "title": "A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Platinum Resistant Ovarian Cancer", "Fallopian Tube Cancer", "Renal Cell Carcinoma (RCC)", "Papillary Renal Cell Carcinoma (Prcc)", "Uterine Serous Carcinoma (USC)", "NSCLC (Non-small Cell Lung Cancer)", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "SIM0505 for injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NextCure, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 738, "start_date": "2025-02-26", "completion_date": "2028-08", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-06T21:03:25.826Z", "location_count": 9, "location_summary": "Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 6 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "New Orleans", "state": "Louisiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06792552" }, { "nct_id": "NCT06330064", "title": "A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent or Metastatic Solid Tumors" ], "interventions": [ { "name": "Ifinatamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 680, "start_date": "2024-04-10", "completion_date": "2028-07-25", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-10-06T21:03:25.826Z", "location_count": 18, "location_summary": "Los Angeles, California • Whittier, California • Skokie, Illinois + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Skokie", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06330064" }, { "nct_id": "NCT05063916", "title": "Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinomas", "Cervix Cancer", "Cervical Cancer" ], "interventions": [ { "name": "AK104", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2022-02-28", "completion_date": "2027-08-01", "has_results": false, "last_update_posted_date": "2026-08-12", "last_synced_at": "2026-10-06T21:03:25.826Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05063916" }, { "nct_id": "NCT02140021", "title": "Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients With Cervical, Vaginal and Vulvar Dysplasia and Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenocarcinoma In Situ", "Cervical Intraepithelial Neoplasia", "Cervical Squamous Cell Carcinoma, Not Otherwise Specified", "Cervical Squamous Intraepithelial Neoplasia", "Early Invasive Cervical Adenocarcinoma", "Early Invasive Cervical Squamous Cell Carcinoma", "High Grade Cervical Squamous Intraepithelial Neoplasia", "High Grade Vaginal Intraepithelial Neoplasia", "Low Grade Vaginal Intraepithelial Neoplasia", "Stage I Cervical Cancer AJCC v8", "Stage I Vaginal Cancer AJCC v8", "Stage I Vulvar Cancer AJCC v8", "Stage IA Cervical Cancer AJCC v8", "Stage IA Vaginal Cancer AJCC v8", "Stage IA Vulvar Cancer AJCC v8", "Stage IA1 Cervical Cancer AJCC v8", "Stage IA2 Cervical Cancer AJCC v8", "Stage IB Cervical Cancer AJCC v8", "Stage IB Vaginal Cancer AJCC v8", "Stage IB Vulvar Cancer AJCC v8", "Stage IB1 Cervical Cancer AJCC v8", "Stage IB2 Cervical Cancer AJCC v8", "Stage II Cervical Cancer AJCC v8", "Stage II Vaginal Cancer AJCC v8", "Stage II Vulvar Cancer AJCC v8", "Stage IIA Cervical Cancer AJCC v8", "Stage IIA Vaginal Cancer AJCC v8", "Stage IIA1 Cervical Cancer AJCC v8", "Stage IIA2 Cervical Cancer AJCC v8", "Stage IIB Cervical Cancer AJCC v8", "Stage IIB Vaginal Cancer AJCC v8", "Stage III Cervical Cancer AJCC v8", "Stage III Vaginal Cancer AJCC v8", "Stage III Vulvar Cancer AJCC v8", "Stage IIIA Cervical Cancer AJCC v8", "Stage IIIA Vulvar Cancer AJCC v8", "Stage IIIB Cervical Cancer AJCC v8", "Stage IIIB Vulvar Cancer AJCC v8", "Stage IIIC Vulvar Cancer AJCC v8", "Stage IV Cervical Cancer AJCC v8", "Stage IV Vaginal Cancer AJCC v8", "Stage IV Vulvar Cancer AJCC v8", "Stage IVA Cervical Cancer AJCC v8", "Stage IVA Vaginal Cancer AJCC v8", "Stage IVA Vulvar Cancer AJCC v8", "Stage IVB Cervical Cancer AJCC v8", "Stage IVB Vaginal Cancer AJCC v8", "Stage IVB Vulvar Cancer AJCC v8", "Vaginal Adenocarcinoma", "Vulvar Adenocarcinoma", "Vulvar High Grade Squamous Intraepithelial Lesion", "Vulvar Intraepithelial Neoplasia", "Vulvar Squamous Cell Carcinoma", "Vulvar Squamous Intraepithelial Lesion" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 409, "start_date": "2014-10-27", "completion_date": "2025-07-08", "has_results": false, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-10-06T21:03:25.826Z", "location_count": 2, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02140021" }, { "nct_id": "NCT02059265", "title": "Dasatinib in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, Endometrial or Peritoneal Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Clear Cell Adenocarcinoma", "Ovarian Clear Cell Cystadenocarcinoma", "Recurrent Fallopian Tube Carcinoma", "Recurrent Ovarian Carcinoma", "Recurrent Primary Peritoneal Carcinoma", "Recurrent Uterine Corpus Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 35, "start_date": "2014-02-14", "completion_date": "2023-06-26", "has_results": true, "last_update_posted_date": "2023-08-01", "last_synced_at": "2026-10-06T21:03:25.826Z", "location_count": 227, "location_summary": "Anchorage, Alaska • Auburn, California • Berkeley, California + 154 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Auburn", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02059265" }, { "nct_id": "NCT00025467", "title": "Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Adenoacanthoma", "Endometrial Adenocarcinoma", "Endometrial Adenosquamous Cell Carcinoma", "Endometrial Clear Cell Carcinoma", "Endometrial Papillary Serous Carcinoma", "Recurrent Endometrial Carcinoma" ], "interventions": [ { "name": "thalidomide", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 60, "start_date": "2001-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-24", "last_synced_at": "2026-10-06T21:03:25.826Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025467" }, { "nct_id": "NCT04772989", "title": "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Non Small Cell Lung Cancer (NSCLC)", "Melanoma", "Cervical Cancer", "Multiple Myeloma", "Lymphoma, Non-Hodgkin", "Diffuse Large B Cell Lymphoma (DLBCL)", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Cancer" ], "interventions": [ { "name": "AB308", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 94, "start_date": "2021-03-19", "completion_date": "2025-08-25", "has_results": false, "last_update_posted_date": "2025-08-28", "last_synced_at": "2026-10-06T21:03:25.826Z", "location_count": 15, "location_summary": "Los Angeles, California • Jacksonville, Florida • Goshen, Indiana + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Goshen", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT04772989" }, { "nct_id": "NCT05799274", "title": "Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer or Other Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers", "Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer (NSCLC)", "Esophageal Squamous Cell Carcinoma", "Cervical Cancer", "Endometrial Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "RAD301 ([68Ga]-RAD301)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Radiopharm Theranostics, Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-11-09", "completion_date": "2026-09", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-10-06T21:03:25.826Z", "location_count": 2, "location_summary": "Princeton, New Jersey • The Bronx, New York", "locations": [ { "city": "Princeton", "state": "New Jersey" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05799274" }, { "nct_id": "NCT02368067", "title": "Improved Method of Detecting Cancer Metastases", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endometrial Carcinoma" ], "interventions": [ { "name": "Standard of Care Sentinal Node Dye", "type": "PROCEDURE" }, { "name": "Study Sentinal Node Dye", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Southeastern Regional Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2014-06", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2015-02-20", "last_synced_at": "2026-10-06T21:03:25.826Z", "location_count": 1, "location_summary": "Newnan, Georgia", "locations": [ { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02368067" } ] }